These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 27264764

  • 1. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 2. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 3. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T, Gando S, Mizugaki A, Yanagida Y, Jesmin S, Yokota H, Ieko M.
    Thromb Res; 2013 Jul 01; 132(1):e64-9. PubMed ID: 23726093
    [Abstract] [Full Text] [Related]

  • 4. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
    Hayakawa M, Sawamura A, Gando S, Jesmin S, Naito S, Ieko M.
    Thromb Res; 2012 Dec 01; 130(6):906-13. PubMed ID: 22353215
    [Abstract] [Full Text] [Related]

  • 5. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
    Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH.
    Ann Hematol; 2005 Oct 01; 84(10):675-80. PubMed ID: 16007424
    [Abstract] [Full Text] [Related]

  • 6. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, Okugawa Y, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Shiku H, Nobori T.
    Clin Appl Thromb Hemost; 2001 Jul 01; 7(3):229-33. PubMed ID: 11441985
    [Abstract] [Full Text] [Related]

  • 7. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature.
    Totoki T, Ito T, Kakuuchi M, Yashima N, Maruyama I, Kakihana Y.
    Thromb J; 2022 Feb 07; 20(1):6. PubMed ID: 35130927
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 07; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 9. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 Oct 07; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 10. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.
    Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, Sakata Y.
    Int J Hematol; 2006 Dec 07; 84(5):398-405. PubMed ID: 17189219
    [Abstract] [Full Text] [Related]

  • 11. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 07; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 12. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug 07; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 13. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep 07; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 14. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 15. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.
    Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S.
    Crit Care Med; 2001 Jun 06; 29(6):1164-8. PubMed ID: 11395595
    [Abstract] [Full Text] [Related]

  • 16. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 06; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 17. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 06; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 18. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul 06; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

  • 19. Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
    Dubis J, Zuk N, Grendziak R, Zapotoczny N, Pfanhauser M, Witkiewicz W.
    Blood Coagul Fibrinolysis; 2014 Apr 06; 25(3):226-31. PubMed ID: 24378973
    [Abstract] [Full Text] [Related]

  • 20. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 06; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.